| Patients Data |
N (%) |
| Number of patients |
35 (100) |
| Platinum+pemetrexed |
18 (51.4) |
| Platinum+gemcitabina |
17 (48.6) |
| Clinical Benefit |
| Yes |
24 (68.6) |
| No |
9 (26.5) |
| Unknown |
2 (5.9) |
| Toxicity (GR3-4) |
| Anemia |
0 (0) |
| Neutropenia |
1 (2.9) |
| Thrombocytopenia |
0 (0) |
| Rensponse to the first line |
| Complete response |
1 (2,9) |
| Partial response |
10(28.6) |
| Stationarity of disease |
13 (37.1) |
| Progression of disease |
11 (31.4) |
| First line chemotherapy |
25 (71.4) |
| Pemetrexed |
1 (4) |
| Docetaxel |
0 (0) |
| Erlotinib |
24 (96) |
| Other |
0 (0) |
| Clinical Benefit |
| Yes |
6 (24) |
| No |
14 (56) |
| Unknown |
5(20) |
| Toxicity (GR3-4) |
| Anemia |
1 (0,9) |
| Neutropenia |
1 (0,9) |
| Thrombocytopenia |
1 (0,9) |
| Response to the second line |
| Complete Response |
0 (0) |
| Partial Response |
5 (20) |
| Stationarity of Disease |
5 (20) |
| Progression of Disease |
14 (60) |
|
